BMRN
BIOMARIN PHARMACEUTICAL INC
$57.91
+2.40%
$10.9B
No data for this timeframe.
Vol
Market Cap$10.9B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (79%)
Inst. Holders10 funds
Inst. Value$2.9B
Inst. Activity3 buys / 2 sells
Insider Activity0B / 4S
Insider Net $-$3.2M
SEC Reports5
Recent Activity
Jun 9, 2026
short_volume
Short Volume: BMRN — 63.5% short (0.6M / 0.9M)
Short: 577,023 | Exempt: 2 | TRF Vol: 908,828 | Short Ratio: 63.5% | Off-exchange volume (dark pool
Jun 4, 2026
SEC
BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four pro
8-K — Impact 2/10
Jun 2, 2026
Insider
Countouriotis Athena sold 7,490 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
Insider
Walbert Timothy P sold 7,490 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
Insider
Enyedy Mark J sold 7,490 shares
Director @ $0.00 ($0.00)
Apr 27, 2026
SEC
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal th
8-K — Impact 8/10
Apr 21, 2026
SEC
BioMarin Pharmaceutical Inc. filed a definitive proxy statement (DEFA14A) for its annual shareholder meeting, which is r
DEFA14A — Impact 2/10
Inst.
NORGES BANK — NEW
7,531,080 shares ($447.6M)
Price Targets
$87.85
+51.7% upside
Strong Buy
Current $57.91
Low $50.00
Median $85.50
High $120.00
26 analysts
$50.00
$120.00
Analyst Ratings
11Strong Buy
16Buy
7Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 19, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 19, 2026 | Citigroup | INITIATE | Buy |
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral → Neutral |
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.96 ▲ +1162.1% | $0.77 — $1.17 | -34% YoY | 15 |
| Next Q | $1.49 ▲ +8.3% | $1.36 — $1.71 | 1140% YoY | 15 |
| Current FY | $4.94 ▲ +6.4% | $4.86 — $5.01 | 57% YoY | 18 |
| Next FY | $6.46 ▼ -4.3% | $4.52 — $7.58 | 31% YoY | 18 |
Latest Reports
NEUTRAL
8-K
2/10
BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four pro
Jun 4, 2026
BULLISH
8-K
8/10
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal th
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.1B | — |
| DODGE & COX | $866.0M | — |
| NORGES BANK | $447.6M | NEW |
| MORGAN STANLEY | $137.6M | ADD |
| FMR LLC | $109.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Countouriotis Athena | A | $0.00 |
| Jun 2, 2026 | Walbert Timothy | A | $0.00 |
| Jun 2, 2026 | Enyedy Mark | A | $0.00 |
| Jun 2, 2026 | HOMBACH ROBERT | A | $0.00 |
| Jun 2, 2026 | Dere Willard | A | $0.00 |
10 institutional holders with $2.9B total value (48,098,619 shares) as of 2025-Q4. Top holders: VANGUARD, DODGE, NORGES. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 18,127,847 | $1.1B | 37.7% | — |
| 2 | DODGE & COX | 14,572,384 | $866.0M | 30.3% | — |
| 3 | NORGES BANK | 7,531,080 | $447.6M | 15.7% | NEW |
| 4 | MORGAN STANLEY | 2,315,620 | $137.6M | 4.8% | ADD +67.7% |
| 5 | FMR LLC | 1,837,071 | $109.2M | 3.8% | DOUBLED +367.7% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,423,712 | $84.6M | 3.0% | NEW |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1,324,971 | $78.7M | 2.8% | TRIM -30.0% |
| 8 | BANK OF AMERICA CORP /DE/ | 864,512 | $51.4M | 1.8% | — |
| 9 | TWO SIGMA INVESTMENTS, LP | 69,766 | $4.1M | 0.1% | TRIM -55.7% |
| 10 | WELLS FARGO & COMPANY/MN | 31,656 | $1.9M | 0.1% | TRIM -33.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 7,531,080 | — | $447.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,380,444 | 2,315,620 | +67.7% | $137.6M | 2025-Q4 |
| FMR LLC | DOUBLED | 392,815 | 1,837,071 | +367.7% | $109.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,893,571 | 1,324,971 | -30.0% | $78.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 157,588 | 69,766 | -55.7% | $4.1M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 2,428,689 | 1,380,444 | -43.2% | $74.8M | 2025-Q3 |
| FMR LLC | TRIM | 546,100 | 392,815 | -28.1% | $21.3M | 2025-Q3 |
| NORGES BANK | EXIT | 2,043,879 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 1,042,885 | 2,428,689 | +132.9% | $133.5M | 2025-Q2 |
| NORGES BANK | NEW | — | 2,043,879 | — | $112.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 895,771 | 1,806,771 | +101.7% | $99.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 759,388 | 147,596 | -80.6% | $8.1M | 2025-Q2 |
| Elliott Investment Management L.P. | EXIT | 3,500,338 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 774,213 | 1,936,458 | +150.1% | $136.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 435,871 | 895,771 | +105.5% | $63.3M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 232,808 | 759,388 | +226.2% | $53.7M | 2025-Q1 |
| FMR LLC | DOUBLED | 238,157 | 541,512 | +127.4% | $38.3M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 57,943 | 38,766 | -33.1% | $2.7M | 2025-Q1 |
| NORGES BANK | EXIT | 3,569,831 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 921,171 | 1,523,633 | +65.4% | $100.1M | 2024-Q4 |
| MORGAN STANLEY | ADD | 870,224 | 1,340,432 | +54.0% | $88.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 1,600,597 | 774,213 | -51.6% | $50.9M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,401,628 | — | $98.5M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 1,196,763 | 870,224 | -27.3% | $61.2M | 2024-Q3 |
15 unique insiders with 4 transactions. Net insider value: -$3.2M ($0.00 bought, $3.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Countouriotis Athena | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | Walbert Timothy P | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | Enyedy Mark J | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | HOMBACH ROBERT J. | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | Dere Willard H | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | Bodem Barbara W. | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | CLARK IAN T | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | ANDERSON ELIZABETH M | Director | A | 7,490 | $0.00 | $0.00 |
| Jun 2, 2026 | Ho Maykin | Director | A | 7,490 | $0.00 | $0.00 |
| May 20, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | F | 2,318 | $50.20 | $116.4K |
| May 7, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | SELL | 3,281 | $53.85 | $176.7K |
| Mar 18, 2026 | Davis George Eric | EVP, Chief Legal Officer | F | 1,273 | $56.05 | $71.4K |
| Mar 17, 2026 | Hardy Alexander | Chief Executive Officer | F | 4,252 | $56.05 | $238.3K |
| Mar 17, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | F | 1,629 | $56.05 | $91.3K |
| Mar 17, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | F | 1,245 | $56.05 | $69.8K |
| Mar 17, 2026 | Mueller Brian | EVP, Chief Financial Officer | F | 2,117 | $56.05 | $118.7K |
| Mar 17, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | F | 1,693 | $56.05 | $94.9K |
| Mar 16, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | A | 15,410 | $0.00 | $0.00 |
| Mar 16, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | A | 35,680 | $0.00 | $0.00 |
| Mar 16, 2026 | Mueller Brian | EVP, Chief Financial Officer | A | 44,600 | $0.00 | $0.00 |
| Mar 16, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | A | 19,150 | $0.00 | $0.00 |
| Mar 16, 2026 | Hardy Alexander | Chief Executive Officer | A | 62,440 | $0.00 | $0.00 |
| Mar 16, 2026 | Hardy Alexander | Chief Executive Officer | A | 89,200 | $0.00 | $0.00 |
| Mar 16, 2026 | Mueller Brian | EVP, Chief Financial Officer | A | 18,740 | $0.00 | $0.00 |
| Mar 16, 2026 | Davis George Eric | EVP, Chief Legal Officer | F | 7,177 | $58.51 | $419.9K |
| Mar 16, 2026 | Davis George Eric | EVP, Chief Legal Officer | A | 14,570 | $0.00 | $0.00 |
| Mar 16, 2026 | Davis George Eric | EVP, Chief Legal Officer | A | 34,690 | $0.00 | $0.00 |
| Mar 16, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | A | 14,990 | $0.00 | $0.00 |
| Mar 16, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | A | 45,600 | $0.00 | $0.00 |
| Mar 16, 2026 | Hubbard Cristin | EVP, Chief Commercial Officer | A | 36,680 | $0.00 | $0.00 |
| Mar 13, 2026 | Mueller Brian | EVP, Chief Financial Officer | F | 9,945 | $58.51 | $581.9K |
| Mar 13, 2026 | Hardy Alexander | Chief Executive Officer | F | 2,941 | $58.51 | $172.1K |
| Mar 13, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | F | 9,109 | $58.51 | $533.0K |
| Mar 11, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | SELL | 16,486 | $60.46 | $996.7K |
| Feb 26, 2026 | Davis George Eric | EVP, Chief Legal Officer | SELL | 26,061 | $61.36 | $1.6M |
| Feb 26, 2026 | Friberg Gregory R | EVP, Chief R&D Officer | SELL | 6,326 | $60.38 | $381.9K |
| Feb 25, 2026 | Guyer Charles Greg | EVP, Chief Technical Officer | A | 6,176 | $0.00 | $0.00 |
| Feb 25, 2026 | Davis George Eric | EVP, Chief Legal Officer | A | 6,177 | $0.00 | $0.00 |
| Feb 25, 2026 | Mueller Brian | EVP, Chief Financial Officer | A | 6,683 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 3 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
2/10
BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders a
Jun 4, 2026
BULLISH
8-K
8/10
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction,
Apr 27, 2026
NEUTRAL
DEFA14A
2/10
BioMarin Pharmaceutical Inc. filed a definitive proxy statement (DEFA14A) for its annual shareholder
Apr 21, 2026
MIXED
INST-CLUSTER
6/10
In Q4 2025, three major institutions — including sovereign wealth fund Norges Bank and passive giant
Feb 28, 2026
NEUTRAL
CLUSTER
4/10
Two senior executives at BioMarin Pharmaceutical sold shares in the past week, with total open-marke
Feb 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (79% buy). Based on 34 analysts: 11 strong buy, 16 buy, 7 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$87.85 mean target
+51.7% upside
Strong Buy (1.69)
$50.00 Low
$120.00 High
| Metric | Value |
|---|---|
| Current Price | $57.91 |
| Target Low | $50.00 |
| Target Mean | $87.85 |
| Target Median | $85.50 |
| Target High | $120.00 |
| # Analysts | 26 |
| Recommendation | Strong Buy (1.69) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.96 | $0.77 | $1.17 | -33.6% | +1162.1% | 1↑ 1↓ | $0.9B | 13.1% | 15 |
| Next Q 2026-09-30 |
$1.49 | $1.36 | $1.71 | 1140.2% | +8.3% | 3↑ 3↓ | $1.1B | 36.5% | 15 |
| Current FY 2026-12-31 |
$4.94 | $4.86 | $5.01 | 56.7% | +6.4% | 3↑ 6↓ | $3.9B | 21.0% | 18 |
| Next FY 2027-12-31 |
$6.46 | $4.52 | $7.58 | 30.9% | -4.3% | 2↑ 5↓ | $4.5B | 14.5% | 18 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.956 | |
| 7d ago | $0.961 | -0.005 |
| 30d ago | $-0.090 | +1.046 |
| 60d ago | $0.925 | +0.031 |
| 90d ago | $0.925 | +0.031 |
15 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 19, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 19, 2026 | Citigroup | INITIATE | — | Buy |
| May 18, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 5, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | RBC Capital | REITERATE | Sector Perform | Sector Perform |
| May 5, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 11, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 2, 2026 | Freedom Broker | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
| Feb 24, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 18, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Canaccord Genuity | UPGRADE | Hold | Buy |
| Dec 23, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 16 | 7 | 0 | 0 | 79% | |
| May 1, 2026 | 10 | 16 | 6 | 0 | 0 | 81% | |
| Apr 1, 2026 | 10 | 15 | 6 | 0 | 0 | 81% | |
| Mar 1, 2026 | 9 | 16 | 7 | 0 | 0 | 78% | |
| Feb 1, 2026 | 9 | 16 | 7 | 0 | 0 | 78% | |
| Jan 1, 2026 | 10 | 15 | 7 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: BMRN — 63.5% short (0.6M / 0.9M)
Short: 577,023 | Exempt: 2 | TRF Vol: 908,828 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: BMRN — 65.2% short (0.4M / 0.5M)
Short: 357,432 | Exempt: 0 | TRF Vol: 548,012 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: BMRN — 55.9% short (0.5M / 0.9M)
Short: 510,410 | Exempt: 601 | TRF Vol: 913,773 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: BMRN — 56.8% short (0.4M / 0.7M)
Short: 417,347 | Exempt: 48 | TRF Vol: 735,321 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: BMRN — 62.3% short (0.6M / 0.9M)
Short: 567,962 | Exempt: 0 | TRF Vol: 912,323 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: BMRN — 57.1% short (0.7M / 1.3M)
Short: 734,660 | Exempt: 27 | TRF Vol: 1,286,677 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: BMRN — 62.7% short (1.3M / 2.1M)
Short: 1,323,843 | Exempt: 284 | TRF Vol: 2,112,295 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: BMRN — 59.5% short (0.4M / 0.7M)
Short: 429,268 | Exempt: 199 | TRF Vol: 721,809 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: BMRN — 69.5% short (0.8M / 1.1M)
Short: 770,106 | Exempt: 645 | TRF Vol: 1,108,077 | Short Ratio: 69.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
Clinical Trial
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 18, 2026
clinical_trial_readout
T-90d Trial Readout: Vosoritide (Phase 3)
Trial: Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Sponsor: BioMarin Pharmaceutical
Phase: Phase 3 | Statu
May 18, 2026
dark_pool
Dark Pool: BMRN — 4.8M shares, 79,783 trades
Week starting 2026-05-18. Total ATS volume: 4,834,753 shares across 79,783 trades.
May 13, 2026
clinical_trial_readout
T-90d Trial Readout: Vosoritide (Phase 3)
Trial: Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Sponsor: BioMarin Pharmaceutical
Phase: Phase 3 | Statu
May 11, 2026
dark_pool
Dark Pool: BMRN — 3.1M shares, 57,923 trades
Week starting 2026-05-11. Total ATS volume: 3,133,438 shares across 57,923 trades.
May 7, 2026
short_volume
Short Volume: BMRN — 58.8% short (0.4M / 0.7M)
Short: 416,981 | Exempt: 0 | TRF Vol: 708,679 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Vosoritide (Phase 3)
Trial: Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Sponsor: BioMarin Pharmaceutical
Phase: Phase 3 | Statu
Mar 26, 2026
Enforcement
Ascendis Pharma A/S v. Biomarin Pharmaceutical Inc.
Court ruling from Court of Appeals for the Federal Circuit. Docket: 26-1026
May 24, 2018
FDA
PALYNZIQ